Cantel Medical — Investor Presentation (November 2014)
23 slides from Cantel Medical's investor presentation, Nov 18, 2014

Slide 1: Infection Prevention & Control Matters – Investor Presentation

Slide 2: $489M NYSE Leader in Infection Prevention & Control
@ CANTEL MEDICAL $489M NYSE Leader in Infection Prevention & Control+... v The only pure-play in the growing ~$45B Global Infection Prevention & Control Market (“IP&C”) Y Government and industry focus on healthcare associated infections and IP&C generally is a growth driver and largely shields our m

Slide 3: Our Mission Statement
@ CANTEL MEDICAL Our Mission Statement Our Purpose Cantel Medical is dedicated to delivering innovative infection prevention and contro (IP&C) products and services for patients, caregivers, and other healthcare providers, which improve outcomes and help save lives. Our Business Priorities New Produ

Slide 4: Category Leadership and Strong Performance
ZB CANTEL MEDICAL CATEGORY ‘STRONG LEADERSHIP PERFORMANCE Endoscopy: = Leader in automated endoscope reprocessing systems and procedural disposable products Water Purification & Filtration: = Leading share in water purification systems to dialysis facilities as well as a suite of sterilants and filt

Slide 5: Infection Prevention & Control Focus
@CANTEL MEDICAL Infection Prevention & Control Focus IP&C Device Purification & Disposable Management Filtration Products Endoscopy & Medical Water Dental, Hospital, Dialyzer Reprocessing Purification & Sterility Assurance Therapeutic Filters Medivators Mar Cor Purification Crosstex; SPS Medical Che

Slide 6: Portfolio - Three Major Segments
@ CANTEL MEDICAL lio - Three Major Segments Fiscal Year Ending July 31, 2014 Net Sales 8.7M Operating Income $87.0M* Healtheare Healthcare Disposables : Disposables Dialysis ‘$101.8 Dialysis $18.7 376. AllOther $20.9 21%. asa) 6% All Other 1% $6.1 21% % Water Endoscopy Water Endoscopy Purification $

Slide 7: History of Strong Growth & Profitability
@ CANTEL MEDICAL of Strong Growth & Strong cash flow generation funds acquisition program with modest leverage cacr 103 - "44 $500 $450 $400 $350 $300 $250 $200 $150 $100 $60 - SO rv0s | FY'04 | FY'0S | FY'0G | FY'O7 | FYB | FYOO | FYO [FYtI"] FY2 | FYI | FY4 | (Gams Net Sales $94.0 | $123.0 $137.2

Slide 8: Multi-Prong Strategies for Sustainable Growth
Multi-Prong Strategies for Sustainable Growth Market Expansion Strategic New Acquisitions Products Continuous Improvement

Slide 9: Significant Global Investment in Sales & Marketing
@ CANTEL MEDICAL ifica nt Global Investment Total spending in sales and marketing has more than doubled over last five years despite the economic downturn Significant expansion of United States direct sales teams - Endoscopy at full scale, currently growing Water Purification and Healthcare Disposab

Slide 10: Product Development Investment
Sm CANTEL MEDICAL Investment = Product Development spending has grown by more than two and a half times over the last five years = Have industry leading portfolio of endoscope reprocessors - launching 3 new product platforms in 2014-2015: Advantage Plus Pass-Through, RapidAER, and ISA WD - all with

Slide 11: Acquisitions in All Core Segments
(a CANTEL MEDICAL ~ B : In All Core Segments Acquisition of PuriCore International Ltd. (UK) and IMS (Italy) brought new EU capital equipment and chemistry products and local EU manufacturing while accelerating international go-direct strategies Byrne Medical, now called Medivators Procedural Produc

Slide 12: Long-term Growth Drivers
=~ B (a CANTEL MEDICAL term Growth Drivers Endoscopy Large global addressable markets totaling >$4 billion for existing product portfolio Penetration and adoption of procedural products remains a large opportunity - still at early stages. Global adoption of proprietary, single-shot chemistry for AER

Slide 13: Financial Success of Growth Strategy
@ CANTEL MEDICAL $in millions, except Fiscal Years Ending July 34, 2009 2010 2011 2012 2013 per share data 2008 Net Sales $249.4 Gross Profit $87.6 Gross Margin 35.1% EBITDAS' $31.8 Op. Profit? $18.0 Net Income $8.7 Diluted EPS® $0.24 $260.1 $274.0 $321.7 $386.5 $425.0 $99.5 $111.0 $1228 $164.2 $183

Slide 14: Strong Cash Flow Generation
@ CANTEL MEDICAL : Cash Flow Generation Ge eer ease! Fiscal Year Ending July 31, 2007 2008 2009-2010 —-2011_—«2012—«2013 «2014 Total Assets $263.7 $279.2 $277.9 $280.7 $321.4 $434.8 $487.7 $536.1 Current Ratio Ae) eR) ABH Se) AGT aH 2.5: Equity $155.1 $168.7 $187.1 $209.4 $234.3 $275.9 $321.1 $365.2

Slide 15: Management Team
@ CANTEL MEDICAL “Jorgen 8. Hansen Erie W. Nodiff e President CraigA. Sheldon Andrew A. Krakauer EERO Hr SSIGCHE Chief Execut VP. Corp Regulatory Affairs & QA

Slide 16: Dedicated to Infection Prevention & Control & Patient Safety
@ CANTEL MEDICAL v Dedicated to Infection Prevention & Control & Patient Safety * Our mission is to reduce healthcare associated infections, improve patient safety and outcomes, and help save lives "Strategic plan to double sales and profits from FY14 - FY18: Year 1 ahead of plan = Initial years sig

Slide 17: Growing ~$45B Global Market in Infection Prevention & Control
@ CANTEL MEDICAL Y Growing ~$45B Global Market in Infection Prevention & Control = Pure-play focus = Fragmented nature creates opportunities for further growth and expansion Y $489M NYSE Specialty Infection Prevention & Control Leader* = Strong, recession-buffered core business with high future grow

Slide 18: Appendix
B CANTEL MEDICAL APPENDIX

Slide 19: Selected Acquired Product Portfolio - Endoscopy
@ CANTEL MEDICAL [Selected Acquired Product Portfolio - Endoscopy Procedural Products PuriCore Int!| Limited P Wsroup |

Slide 20: Healthcare Disposables
@ CANTEL MEDICAL jalthcare Disposables rility / Products it-Based Water Disinfection Products G ConFirm. Monitoring Systems, Inc.

Slide 21: Categories of Infection Prevention & Control
) %m CANTEL MEDICAL Q of Infection Prevention & Disinfectants & Cleaners: Disposables Masks / Headwear ‘Ar & Water Quality Protective Apparel jens ays Ar fitaton systems Germicidal cleaners Disposable surgical prodictsNuse/MO/SurgLab Hats Negalive pressure isclation Lab gowns ‘Smoke ewcustrs nershoe

Slide 22: Medivators Endoscope Reprocessing Products
B CANTEL MEDICAL ‘Scope Buddy Intercept Medivators Procedural Medivators Endoscope Reprocessing Products Products (Byrne Medical) Principally in Post-Procedure, Reprocessing Area Treatment Room Sterile Processing Department / Nurses Physicians & Nurses 22

Slide 23: Sales by Product, Customer, Segment
@ CANTEL MEDICAL by Product, Customer, Infection Prevention & Control Focus Healthcare & Life Sciences Orientation 4 Consumables includes service. Spits represent 12 months ending July 34, 2024. 2 Acquisition of Minntech Corporation in September 2001 is represented in Endoscopy, Dialysis, and Therap
Source: SEC EDGAR · 8-K filed Nov 18, 2014
More decks from Cantel Medical Corp
Merger or Acquisition (January 2021)16 slides · Jan 12, 2021
Investor Presentation (December 2020)32 slides · Dec 10, 2020
Investor Presentation (January 2020)31 slides · Jan 9, 2020
Merger or Acquisition (July 2019)17 slides · Jul 30, 2019
Investor Presentation (March 2019)34 slides · Mar 22, 2019
Investor Presentation (January 2016)31 slides · Jan 14, 2016